The renin-angiotensin system (RAS) plays a pivotal role in vasoconstriction, sodium reabsorption and kidney development. Moreover, RASE is involvements in cardiovascular and renal tissue remodeling. Not long ago, angiotensin II (Ang II) was believed to be produced mainly in the pulmonary vessels and delivered to other tissues via plasma. Instead, Ang II is now thought to be produced in the vicinity of its receptors by local renin and Ang I converting enzyme (ACE). While a variety of extrarenal tissues are now recognized to have the potential for synthesizing renin, the functional role of such local RAS is yet to be established. This is because it is difficult to evaluate the functional significance of local versus systemic RAS in vivo, although indirect evidence suggests distinct regulation of systemic (circulating) and local (renal) RAS. Thus, in most experimental models and human disease in which ACE inhibitors attenuate progression of renal failure, circulating (plasma) renin is not unregulated. Recently, the PI established an in vivo system for ~regionally nullifying~ a gene of interest whereby adjacent areas within the same organ, including the heart and kidney, either possess or are devoid of expression of the gene of interest. The projects proposed here will utilize conventional as well as the new regionally-mutated mice to evaluate the PI~s hypotheses that alternative renin substrates exist; that local intra- adrenal (not circulating) renin regulates aldosterone synthesis and Ang II-dependent functions in the kidney are regulated by renal (not circulating) renin. The PI will evaluate pathophysiologic settings, testing the hypothesis that progressive parenchymal renal damage depends on local RAS whereas parenchymal cardiac disease depends on circulating (not local) RAS.
| Kaseda, Ryohei; Jabs, Kathy; Hunley, Tracy E et al. (2015) Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism 64:263-73 |
| Yamamoto, Suguru; Zhong, Jiayong; Yancey, Patricia G et al. (2015) Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis 242:56-64 |
| Zhong, Jianyong; Yang, Hai-Chun; Kon, Valentina et al. (2014) Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts. Lab Invest 94:633-44 |
| Yamamoto, Suguru; Kon, Valentina (2014) Chronic kidney disease induced dysfunction of high density lipoprotein. Clin Exp Nephrol 18:251-4 |
| Yang, Hai-Chun; Fogo, Agnes B (2014) Mechanisms of disease reversal in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis 21:442-7 |
| Zuo, Yiqin; Chun, Bongkwon; Potthoff, Sebastian A et al. (2013) Thymosin ?4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int 84:1166-75 |
| Miyazawa, Tomoki; Zeng, Fenghua; Wang, Suwan et al. (2013) Low nitric oxide bioavailability upregulates renal heparin binding EGF-like growth factor expression. Kidney Int 84:1176-88 |
| López-Guisa, Jesús M; Cai, Xiaohe; Collins, Sarah J et al. (2012) Mannose receptor 2 attenuates renal fibrosis. J Am Soc Nephrol 23:236-51 |
| Yamamoto, Suguru; Yancey, Patricia G; Ikizler, T Alp et al. (2012) Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 60:2372-9 |
| Yamaguchi, Ikuyo; Tchao, Bie Nga; Burger, Megan L et al. (2012) Vascular endothelial cadherin modulates renal interstitial fibrosis. Nephron Exp Nephrol 120:e20-31 |
Showing the most recent 10 out of 131 publications
